Announcements Trials
Browse Landscape

Phase

Phase 3 4

Status

Completed 4Withdrawn 2

Sponsor Class

OTHER 5INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 1

Conditions

Crohn Disease 3Lymphoma, Follicular 1

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 394Docetaxel 385Cisplatin 359pembrolizumab 343Bevacizumab 335Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Certolizumab Pegol × Clear all
NCT03357471 2019-10-25

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

UCB Pharma

Phase 3 Completed
70 enrolled 16 charts
Lymphoid

Lymphoma, Follicular

NCT00552058 2018-08-09

Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease

UCB Pharma

Phase 3 Completed
439 enrolled 25 charts

Crohn Disease

NCT00333788 2018-08-07

Welcome2

UCB Pharma

Phase 3 Completed
233 enrolled 31 charts

Crohn Disease

NCT00297648 2011-08-31

MUSIC

UCB Pharma

Phase 3 Completed
89 enrolled 43 charts

Crohn Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡